Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences
November 22 2021 - 8:30AM
Business Wire
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that
it will participate in the following upcoming virtual investor
conferences:
Piper Sandler 33rd Annual Virtual Healthcare Conference
November 30, 2021 Format: Fireside Chat (available today, November
22, at 10:00 a.m. ET via Mirum’s IR site) and
one-on-one-meetings.
4th Annual Evercore ISI HealthconX Conference December 2,
2021 Format: Fireside Chat (December 2 at 3:30 p.m. ET) and
one-on-one meetings.
Visit the Investors and Media section of Mirum’s corporate
website for additional information.
About Mirum Pharmaceuticals, Inc.
Mirum Pharmaceuticals, Inc. is a biopharmaceutical company
dedicated to transforming the treatment of rare liver diseases.
Mirum’s approved medication is LIVMARLI™ (maralixibat) oral
solution, which is approved in the U.S. for the treatment of
cholestatic pruritus in patients with Alagille syndrome one year of
age and older.
Mirum’s late-stage pipeline includes two investigational
treatments for debilitating liver diseases affecting children and
adults. Maralixibat (LIVMARLI), an oral ileal bile acid transporter
(IBAT) inhibitor, is currently being evaluated in clinical trials
for pediatric liver diseases and includes the MARCH Phase 3 study
for progressive familial intrahepatic cholestasis (PFIC) and the
EMBARK Phase 2b study for patients with biliary atresia. In
addition, Mirum has an expanded access program open in Canada,
Australia, the UK and several countries in Europe for eligible
patients with Alagille syndrome.
Mirum has submitted a Marketing Authorization Application to the
European Medicines Agency for maralixibat for the treatment of
cholestatic liver disease in patients with Alagille syndrome.
Mirum’s second investigational treatment, volixibat, also an
oral IBAT inhibitor, is being evaluated in two registrational
studies including the OHANA Phase 2b study for pregnant women with
intrahepatic cholestasis of pregnancy and the VISTAS Phase 2b study
for adults with primary sclerosing cholangitis. Mirum is planning
to launch a Phase 2b study in primary biliary cholangitis later
this year.
To augment its pipeline in cholestatic liver disease, Mirum has
acquired the exclusive option to develop and commercialize gene
therapy programs VTX-803 and VTX-802 for PFIC3 and PFIC2,
respectively, from Vivet Therapeutics SAS, following preclinical
evaluation and investigational new drug-enabling studies.
Follow Mirum on Twitter, Facebook, LinkedIn and Instagram.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20211122006023/en/
Mirum Contacts:
Media: Erin Murphy media@mirumpharma.com
Investors: Ian Clements, Ph.D. ir@mirumpharma.com
Sam Martin Argot Partners ir@mirumpharma.com
Mirum Pharmaceuticals (NASDAQ:MIRM)
Historical Stock Chart
From Mar 2024 to Apr 2024
Mirum Pharmaceuticals (NASDAQ:MIRM)
Historical Stock Chart
From Apr 2023 to Apr 2024